September FDA approvals included Genentech’s Ocrevus Zunovo for multiple sclerosis, AstraZeneca’s Tagrisso for lung cancer and Filspari to slow kidney function decline. Johnson & Johnson’s Tremfya is cleared for ulcerative colitis and Miplyffa and Aqneursa are OK’d for ultra-rare Niemann-Pick disease type C. Other approvals include: Bristol Myers Squibb’s oral Cobenfy for schizophrenia, Eli Lilly’s Ebglyss injection for atopic dermatitis, ready-to-use Boruzu (bortezomib), and FluMist nasal flu vaccine for self or caregiver administration.